Liso-Cel Deemed Cost-Effective as Second-Line Treatment for DLBCL
Liso-cel is cost-effective as second-line therapy for diffuse large B-cell lymphoma, according to researchers. Liso-cel is cost-effective as second-line therapy for diffuse large B-cell lymphoma, according to researchers.